| PIH | Pregnancy-Induced Hypertension |
|---|---|
| SP1 | pregnancy-specific β1-glycoprotein |
| AFLP | acute fatty liver of pregnancy |
| DAP | data acquisition processor; depolarizing afterpotential; diabetes-associated peptide; diaminopimelic... |
| DAPT | diaminophenylthiazole; direct agglutination pregnancy test |
| pregnancy disease of sheep | A highly fatal metabolic disease of well-nourished ewes in the late stages of pregnancy, especially in ewes carrying twin lambs; it is caused by carbohydrate depletion of the blood and tissues, and is characterised by hypoglycaemia, ketonuria, fatty infiltration of the liver, rapid emaciation, coma, and a high death rate. Synonym: lambing paralysis, lambing sickness. (05 Mar 2000) |
|---|---|
| pregnancy, ectopic | A pregnancy that is not in the usual place and is located outside the inner lining of the uterus. A fertilised egg settles and grows in any location other than the inner lining of the uterus. The vast majority of ectopic pregnancies occur in the fallopian tube (95%), however, they can occur in other locations, such as the ovary, cervix, and abdominal cavity. An ectopic pregnancy occurs in about 1 in 60 pregnancies. A major concern with an ectopic pregnancy is internal bleeding. If there is any doubt, seek medical attention promptly. (12 Dec 1998) |
| pregnancy, ectopic, symptoms of | Symptoms of an ectopic pregnancy can often be vague and include vaginal bleeding, abdominal or pelvic pain (usually stronger on one side),shoulder pain, weakness, or dizziness. Weakness, dizziness, and a sense of passing out upon standing can represent serious internal bleeding, requiring immediate medical attention. (12 Dec 1998) |
| pregnancy, high-risk | Pregnancy in which the mother and/or foetus are at greater than normal risk of morbidity or mortality. Causes include lack of adequate prenatal care, previous obstetrical history, pre-existing maternal disease or pregnancy-induced disease, and multiple gestation, as well as advanced maternal age. (12 Dec 1998) |
| pregnancy hormone | <biochemistry, gynaecology> Produced in the corpus luteum, as an antagonist of oestrogens. Promotes proliferation of uterine mucosa and the implantation of the blastocyst, prevents further follicular development. (18 Nov 1997) |
| pregnancy in adolescence | Pregnancy in girls under 19. (12 Dec 1998) |
| pregnancy maintenance | Physiological mechanisms that sustain the state of pregnancy. (12 Dec 1998) |
| pregnancy, multiple | The condition of bearing two or more foetuses simultaneously. (12 Dec 1998) |
| pregnancy outcome | Results of conception and ensuing pregnancy, including live birth, stillbirth, spontaneous abortion, induced abortion. The outcome may follow natural or artificial insemination or any of the various reproduction techniques, such as embryo transfer or fertilization in vitro. (12 Dec 1998) |
| pregnancy planning | Pregnancy planning addresses issues of nutrition, vitamins, body weight, exercise, and potentially harmful medications and illnesses as well as immunizations and genetic counseling. (12 Dec 1998) |
| pregnancy, prolonged | Pregnancy continuing beyond the normal duration; in humans, usually beyond 294 days after the beginning of the last menses. (12 Dec 1998) |
| pregnancy proteins | Proteins produced by organs of the mother or the placenta during pregnancy. They may be either pregnancy specific (present only during pregnancy) or pregnancy associated (always present during pregnancy, but may also be present in individuals undergoing oestrogen therapy, taking oral contraceptives or in patients with certain malignancies.) (12 Dec 1998) |
| pregnancy rate | Ratio of the number of conceptions that occur during a period to the mean number of women of reproductive age. (12 Dec 1998) |
| pregnancy reduction, multifetal | Selective abortion of one or more embryos or foetuses in a multiple gestation pregnancy. The usual goal is to improve the outcome for the remaining embryos or foetuses. (12 Dec 1998) |
| pregnancy-specific beta 1-glycoprotein | A glycoprotein with the electrophoretic mobility of a beta-1 globulin. It is produced by the placental trophoblast and secreted into the maternal bloodstream during pregnancy. It can be detected 18 days after ovulation and its concentration in plasma rises steadily until, at the end of gestation, it reaches 200 mg/ml. It has been proposed as a measure of placental function for fertility control and is a candidate for an early pregnancy test. (12 Dec 1998) |